* G protein-coupled receptors (GPCRs) in the G protein-coupled active state have higher affinity for agonists as compared with when they are in the inactive state, but the molecular basis for this is unclear. We have determined four active-state structures of the b 1 -adrenoceptor (b 1 AR) bound to conformation-specific nanobodies in the presence of agonists of varying efficacy. Comparison with inactive-state structures of b 1 AR bound to the identical ligands showed a 24 to 42% reduction in the volume of the orthosteric binding site. Potential hydrogen bonds were also shorter, and there was up to a 30% increase in the number of atomic contacts between the receptor and ligand. This explains the increase in agonist affinity of GPCRs in the active state for a wide range of structurally distinct agonists.
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* G protein-coupled receptors (GPCRs) in the G protein-coupled active state have higher affinity for agonists as compared with when they are in the inactive state, but the molecular basis for this is unclear. We have determined four active-state structures of the b 1 -adrenoceptor (b 1 AR) bound to conformation-specific nanobodies in the presence of agonists of varying efficacy. Comparison with inactive-state structures of b 1 AR bound to the identical ligands showed a 24 to 42% reduction in the volume of the orthosteric binding site. Potential hydrogen bonds were also shorter, and there was up to a 30% increase in the number of atomic contacts between the receptor and ligand. This explains the increase in agonist affinity of GPCRs in the active state for a wide range of structurally distinct agonists.
G protein-coupled receptors (GPCRs) exist in an ensemble of conformations that can be selectively stabilized by the binding of a ligand and through interactions with signaling molecules such as G proteins (1, 2) . Pharmacology has characterized at least two distinct states of GPCRs, an active state with high affinity for agonists when coupled to G proteins and an inactive state with low affinity for agonists in the absence of G proteins (1) , although a plethora of substates can also exist between these two extremes (3) (4) (5) (6) (7) . The reason why the active state has a high affinity for agonists is unclear because receptor structures in the inactive and active states have been determined with different ligands bound, such as for the b 2 -adrenoceptor (b 2 AR) (8) (9) (10) (11) . Here, we present structures of b 1 AR in the active state and compare them with inactive-state structures (12) bound to the identical ligand to define the structural differences in the orthosteric binding site.
Four crystal structures with overall resolutions between 3.0 and 3.2 Å (table S1) were determined of b 1 AR bound to either Nb80 or Nb6B9, and the overall structures were virtually identical [0.2 to 0.3 Å root mean square deviation (RMSD) for Ca atoms] (Fig. 1 ). Nb80 and Nb6B9 are nanobodies originally developed to stabilize the active state of b 2 AR (8, 10) and bind to b 1 AR because of the high sequence conservation of the receptors. Structures were determined bound to a full agonist (isoprenaline), partial agonists (salbutamol and dobutamine), and a weak partial agonist (cyanopindolol). Isoprenaline, salbutamol, and dobutamine showed an increase in affinity when b 1 AR was coupled to the engineered G protein mini-G s , whereas cyanopindolol bound with similar high affinity in both the presence and absence of mini-G s (Fig. 1) . The overall structure of the b 1 AR-nanobody complexes bound to either agonist or partial agonists is virtually identical to that of the agonist-bound Nb6B9-b 2 AR complex (0.5 Å RMSD of 1601 atoms), and the overall conformational changes are virtually identical. These changes result in the partial occlusion of the orthosteric binding pocket (Fig. 2) , which is consistent with observations on nanobody-bound b 2 AR (8, 10) .
Detailed comparisons were made between the inactive-state structures of b 1 AR with the respective active-state structures bound to the same ligand (Figs. 2 and 3) . In all cases, there was a decrease in the volume (13) of the orthosteric binding site that varied depending on the ligand (Fig. 2 and fig. S1 ). The largest decrease was observed for the full agonist isoprenaline (42%), and the smallest decrease was observed for the weak partial agonist cyanopindolol (24%). The decrease in the volume of the orthosteric binding site when isoprenaline was bound was primarily due to the inward movement of the extracellular ends of H6 and H7, an inward movement and an increase in the H5 bulge at Ser215 5.46 , and the reorientation of residues Phe201 ECL2 and Phe325 7.35 [superscripts refer to the Ballesteros-Weinstein numbers (14) ]. The magnitude of these changes was greatest for the full agonist isoprenaline and smallest for the weak partial agonist cyanopindolol. The pincerlike movement of Phe201 ECL2 and Phe325 7.35 toward the ligand has the largest effect on reducing the volume of the orthosteric binding pocket, with the maximal shift observed in the isoprenaline structure of 3.1 Å for Phe201 ECL2 and 2.5 Å for Phe325 7.35 (measured at the CZ atom of the side chain). The movement of Phe201 ECL2 appeared to correlate with the structure of the ligand bound because in all cases it formed van der Waals contacts with the ligand. By contrast, Phe325 7.35 was not within van der Waals contact with any of the four ligands and moved as a consequence of the inward tilt of H7.
The reduction in the volume of the orthosteric binding pocket correlated with an overall reduction in the average distance between atoms in the ligand and receptor by 0.1 to 0.3 Å. Amino acid residues in H3, H5, H6, H7, and ECL2 (and H2 for dobutamine) were all involved in contributing to ligand-receptor contacts, but there was no clear pattern as to which regions of the receptor changed most substantially ( Fig. 3 and fig.  S2 ). Side chains were up to 1.2 Å closer to the ligand in the active state compared with the inactive state. In a number of instances, changes resulted in the strengthening of hydrogen bonds. For example, Asn310
6.55 was predicted to make a weak hydrogen bond to the para-hydroxyl group of isoprenaline (3.5 Å between donor and acceptor) in the inactive state, which changed to 2.8 Å in the active state. In the active-state structures containing dobutamine and salbutamol, the distance to Ser215 5.46 was 0.8 Å shorter for both ligands, allowing hydrogen bond formation; the hydrogen bond to Ser211 5.42 also shortened by 0.7 Å to the para hydroxyl in salbutamol but remained unchanged to the meta hydroxyl in dobutamine. Most of the observed differences are due to the contraction of the binding pocket, whereas the substantial shortening of the hydrogen bond between Ser211 5.42 and salbutamol is due to a rotamer change. Although all the ligand binding pockets contracted upon receptor activation, the changes in ligand-receptor contacts were not conserved, despite the similarity in chemotypes among the four ligands studied. There was a weak correlation between the decrease in volume of the orthosteric binding site and ligand efficacy ( fig. S3 ), particularly if the most similar chemtoypic ligands were compared (cyanopindolol, salbutamol, and isoprenaline). However, there was no correlation between efficacy and the magnitude of ligand affinity increase on receptor activation or the increase in the number of ligand-receptor atomic contacts ( fig. S3 ). Cyanopindolol bound to b 1 AR with similar affinity in both the presence and absence of a coupled G protein (Fig. 1) despite the contraction of the binding pocket and increase in receptor ligand contacts upon activation. This may be a consequence of constraints on the possible conformation change imposed by the rigidity of cyanopindol that prevents the full contraction of the ligand binding pocket by preventing the movement of H7 and the bulge in H5 observed in the other structures ( fig. S1 ).
The role of the partial occlusion of the orthosteric binding site upon activation of b 1 AR was tested by mutagenesis inspired from the active state structure of b 2 AR (8, 10). In b 2 AR, it was proposed that the occlusion of the binding site was a major factor in increasing agonist affinity upon G protein coupling (15) . In particular, Tyr308 7.35 was within van der Waals distance of Phe193 ECL2 on the opposite side of the entrance to the orthosteric binding pocket and had a major effect on decreasing the rates of association and dissociation of ligands in the active state compared with the inactive state (15 (Fig. 4) . Thus, the mutation F325Y
7.35 in b 1 AR was predicted to occlude the entrance to the orthosteric binding pocket and decrease the rate of ligand association, and conversely, F325A
7.35 was predicted to make the entrance wider and increase the rate of ligand association. When the initial rate of 3 Hdihydroalprenolol ( 3 H-DHA) association was measured (Fig. 4) , b 1 AR(F325A) had the same rate as b 1 AR, but b 1 AR(F325Y) had a considerably slower rate of association. However, the affinities (Fig. 4) (fig. S5) .
The increase in affinity of agonist binding to the active state of b 1 AR arises from the increase in the number and/or strength of ligand-receptor contacts (a thermodynamic effect). This is consequently associated with a decrease in the rate of ligand dissociation. Where a native ligand is a large peptide that interacts with extracellular domains, this thermodynamic effect may be the major contributor to the decrease in the rate of ligand dissociation. However, where the ligand is small, such as adrenaline or acetylcholine, the rate of ligand dissociation may also be decreased because of a purely steric blockage of the entrance to the ligand binding pocket (a kinetic effect) (14) . Given the high conservation of both the structure and function of GPCRs (16, 17) , these considerations are likely to apply to other GPCRs that bind diffusible ligands. fig. S2 . structure solution. A.G.W.L. was involved in data processing and structure solution, refinement, and analysis. Manuscript preparation was performed by T.W., A.G.W.L., and C.G.T. The overall project management was by C.G.T. Competing interests: C.G.T. is a shareholder, consultant, and member of the Scientific Advisory Board of Heptares Therapeutics, who also partly funded this work. Data and materials availability: The coordinates and structure factors for all the structures determined have been deposited at the Protein Data Bank (PDB) with the following accession codes (ligand cocrystallized in parentheses): 6H7J (isoprenaline), 6H7L (dobutamine), 6H7M (salbutamol), and 6H7O (cyanopindolol). 
